The mechanism of resistance to favipiravir in influenza

Proceedings of the National Academy of Sciences of the United States of America

Volumn 115, Issue 45, 2018, Pages 11613-11618

  Goldhill, Daniel H ^a,b   Te Velthuis, Aartjan J W ^c   Fletcher, Robert A ^b   Langat, Pinky ^b   Zambon, Maria ^a   Lackenby, Angie ^a   Barclay, Wendy S ^b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Antiviral; Influenza; Polymerase; Resistance; Virus

Indexed keywords

FAVIPIRAVIR; RIBAVIRIN; AMIDE; ANTIVIRUS AGENT; ARGININE; LYSINE; PYRAZINE DERIVATIVE; RNA DIRECTED RNA POLYMERASE; VIRAL PROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE MUTATION; HUMAN; IN VITRO STUDY; INFLUENZA A (H1N1); INFLUENZA A VIRUS (H1N1); MDCK CELL LINE; NONHUMAN; PANDEMIC; PB1 GENE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TRANSCRIPTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; DOG; DRUG EFFECT; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIAL SENSITIVITY TEST; MUTATION; PROTEIN SUBUNIT;

AMIDES; ANIMALS; ANTIVIRAL AGENTS; ARGININE; DOGS; DRUG RESISTANCE, VIRAL; GENE EXPRESSION; INFLUENZA A VIRUS, H1N1 SUBTYPE; LYSINE; MADIN DARBY CANINE KIDNEY CELLS; MICROBIAL SENSITIVITY TESTS; MUTATION; PROTEIN SUBUNITS; PYRAZINES; RNA REPLICASE; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 85056095940     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1811345115     Document Type: Article

References (50)

1. WHO (2018) Influenza (Seasonal) Factsheet. Available at www.who.int/mediacentre/ factsheets/fs211/en. Accessed February 22, 2018.
2. Hurt AC (2014) The epidemiology and spread of drug resistant human influenza viruses. Curr Opin Virol 8:22-29.
3. Bright RA, Shay DK, Shu B, Cox NJ, Klimov AI (2006) Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA 295:891-894.
4. Weinstock DM, Zuccotti G (2009) The evolution of influenza resistance and treatment. JAMA 301:1066-1069.
5. Weinstock DM, Gubareva LV, Zuccotti G (2003) Prolonged shedding of multidrugresistant influenza A virus in an immunocompromised patient. N Engl JMed 348:867-868.
6. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O (2009) Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis 15:155-162.
7. Bloom JD, Gong LI, Baltimore D (2010) Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 328:1272-1275.
8. Hayden F (2009) Developing new antiviral agents for influenza treatment: What does the future hold? Clin Infect Dis 48(Suppl 1):S3-S13.
9. Furuta Y, et al. (2013) Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100:446-454.
10. Furuta Y, Komeno T, Nakamura T (2017) Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93:449-463.
11. Furuta Y, et al. (2002) In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 46:977-981.
12. Furuta Y, et al. (2005) Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 49:981-986.
13. Kiso M, et al. (2010) T-705 (favipiravir) activity against lethal H5N1 influenza A viruses. Proc Natl Acad Sci USA 107:882-887.
14. Sidwell RW, et al. (2007) Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 51:845-851.
15. Sleeman K, et al. (2010) In vitro antiviral activity of favipiravir (T-705) against drug-resistant influenza and 2009 A(H1N1) viruses. Antimicrob Agents Chemother 54:2517-2524.
16. Sangawa H, et al. (2013) Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase. Antimicrob Agents Chemother 57:5202-5208.
17. Naesens L, et al. (2013) Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir). Mol Pharmacol 84:615-629.
18. Smee DF, et al. (2010) Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice. Antimicrob Agents Chemother 54:126-133.
19. Marathe BM, et al. (2016) Combinations of oseltamivir and T-705 extend the treatment window for highly pathogenic influenza A(H5N1) virus infection in mice. Sci Rep 6:26742.
20. Oestereich L, et al. (2014) Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 105:17-21.
21. Oestereich L, et al. (2016) Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J Infect Dis 213:934-938.
22. Delang L, Abdelnabi R, Neyts J (2018) Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res 153:85-94.
23. Pauly MD, Procario MC, Lauring AS (2017) A novel twelve class fluctuation test reveals higher than expected mutation rates for influenza A viruses. eLife 6:e26437.
24. Stevaert A, Naesens L (2016) The influenza virus polymerase complex: An update on its structure, functions, and significance for antiviral drug design. Med Res Rev 36:1127-1173.
25. Baranovich T, et al. (2013) T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 87:3741-3751.
26. Daikoku T, Yoshida Y, Okuda T, Shiraki K (2014) Characterization of susceptibility variants of influenza virus grown in the presence of T-705. J Pharmacol Sci 126:281-284.
27. Bank C, et al. (2016) An experimental evaluation of drug-induced mutational meltdown as an antiviral treatment strategy. Evolution 70:2470-2484.
28. Vanderlinden E, et al. (2016) Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob Agents Chemother 60:6679-6691.
29. Ormond L, et al. (2017) The combined effect of oseltamivir and favipiravir on influenza A virus evolution. Genome Biol Evol 9:1913-1924.
30. Takashita E, et al. (2016) Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir. Antiviral Res 132:170-177.
31. Cheung PP, et al. (2014) Generation and characterization of influenza A viruses with altered polymerase fidelity. Nat Commun 5:4794.
32. Pauly MD, Lyons DM, Fitzsimmons WJ, Lauring AS (2017) Epistatic interactions within the influenza A virus polymerase complex mediate mutagen resistance and replication fidelity. MSphere 2:e00323-17.
33. Delang L, et al. (2014) Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 69:2770-2784.
34. Wang Y, et al. (2016) In vitro assessment of combinations of enterovirus inhibitors against enterovirus 71. Antimicrob Agents Chemother 60:5357-5367.
35. Thompson KAS, Yin J (2010) Population dynamics of an RNA virus and its defective interfering particles in passage cultures. Virol J 7:257.
36. Goldhill D, et al. (2018) Determining the mutation bias of favipiravir in influenza using next-generation sequencing. bioRxiv:10.1101/375378. Preprint, posted July 23, 2018.
37. Pfeiffer JK, Kirkegaard K (2003) A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 100:7289-7294.
38. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R (2011) Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci USA 108:20166-20171.
39. Te Velthuis AJW, Oymans J (November 15, 2017) Initiation, elongation and realignment during influenza virus mRNA synthesis. J Virol, 10.1128/JVI.01775-17.
40. Pflug A, Guilligay D, Reich S, Cusack S (2014) Structure of influenza A polymerase bound to the viral RNA promoter. Nature 516:355-360.
41. te Velthuis AJW (2014) Common and unique features of viral RNA-dependent polymerases. Cell Mol Life Sci 71:4403-4420.
42. Abdelnabi R, et al. (2017) Understanding the mechanism of the broad-spectrum antiviral activity of favipiravir (T-705): Key role of the F1 motif of the viral polymerase. J Virol 91:e00487-17.
43. Pauly MD, Lauring AS (2015) Effective lethal mutagenesis of influenza virus by three nucleoside analogs. J Virol 89:3584-3597.
44. Beaucourt S, Vignuzzi M (2014) Ribavirin: A drug active against many viruses with multiple effects on virus replication and propagation. Molecular basis of ribavirin resistance. Curr Opin Virol 8:10-15.
45. Zhang X, et al. (2014) Drug susceptibility profile and pathogenicity of H7N9 influenza virus (Anhui1 lineage) with R292K substitution. Emerg Microbes Infect 3:e78.
46. Westover JB, et al. (2016) Low-dose ribavirin potentiates the antiviral activity of favipiravir against hemorrhagic fever viruses. Antiviral Res 126:62-68.
47. Wu J, Liu W, Gong P (2015) A structural overview of RNA-dependent RNA polymerases from the Flaviviridae family. Int J Mol Sci 16:12943-12957.
48. Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013) The ambiguous base-pairing and high substrate efficiency of T-705 (favipiravir) ribofuranosyl 5′-triphosphate towards influenza A virus polymerase. PLoS One 8:e68347.
49. Dulin D, et al. (2017) Signatures of nucleotide analog incorporation by an RNAdependent RNA polymerase revealed using high-throughput magnetic tweezers. Cell Rep 21:1063-1076.
50. Imai M, et al. (2017) A highly pathogenic avian H7N9 influenza virus isolated from a human is lethal in some ferrets infected via respiratory droplets. Cell Host Microbe 22: 615-626.e8.